Characterizing HCV primary resistance mutations for direct acting antiviral drug (DAA)

Abstract

Chronic infection with hepatitis C virus affects about 160 million people worldwide and it is leading cause of cirrhosis and other complications. The recent understanding HCV life cycle make possible the development of new drugs; target the viral replication process, such structural proteins like NS3/NS5A and NS5B. Direct acting antiviral drug (DAA) promises to open a new era in treating chronic HCV The emergence of drug-resistant strains of HCV has resulted in the failure of many therapeutic strategies. The aim of this study was to screen resistance mutations for responses for direct acting antiviral drug NS3/ NS5A and NS5B in samples from patients following in a public health laboratory in the State of São Paulo, before the beginning the therapy. Will include a samples of serum from patients with chronic HCV infection, genotyping 1a and 1b, who were starting or following-up public health service treatment and they had never received treatment. PCR and sequence from specifically genome fragment will be done from HCV. (AU)